Search

everythinglearnresearchcommunity

for

Search:↓

Procyanidin B2, a compound derived from Annurca apples, as a potential treatment for pattern hair loss. Several clinical studies were mentioned, which found that procyanidin B2 could increase hair growth, density, and keratin content. Other treatments such as Minoxidil, Finasteride, and RU58841 were not discussed.

Noticeable hair regrowth occurred after two months of using minoxidil and starting finasteride. Users suggested continuing the treatment and considering microneedling for better results.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

The user experienced significant hair regrowth in two months using minoxidil foam and 0.5mg finasteride every other day, despite some side effects. They are considering adjusting the finasteride dosage and possibly adding biotin or dermarolling to their routine.

People are discussing experiences with finasteride for hair loss after being on testosterone for over two years. Users report varying results, with some experiencing regrowth and no side effects, while others emphasize the importance of starting treatment early to prevent further hair loss.

A user shared their positive experience using 2.5mg of finasteride daily for two years, noting significant hair regrowth and no erectile dysfunction issues. They plan to add minoxidil soon, despite some users suggesting that a lower dose of finasteride might be equally effective with fewer side effects.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

A naturally occurring sugar, 2-deoxy-D-ribose, may promote hair growth by forming new blood vessels. There is skepticism about its effectiveness and concerns about potential side effects, with some users comparing it to existing treatments like Minoxidil and finasteride.

A user shared their two-year progress using 2.5mg finasteride daily and minoxidil twice daily, recently adding topical dutasteride. Another user questioned the high finasteride dosage, noting no benefits over 1mg.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

A 28-year-old shared his 2-year hair loss treatment progress using finasteride, minoxidil, dermarolling, and Revita shampoo. He saw significant improvement, especially with minoxidil and dermarolling, and stressed consistency.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

The user is experiencing hair regrowth after two months using topical finasteride, minoxidil spray, and weekly microneedling. They report less hair loss and stronger hair growth.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

Formula 82M, a minoxidil and retinol liquid, improved hair texture and filled in temples with baby hairs for the user, but its high cost and lack of reviews cause concern. Another user mentioned using a similar product, 82F, which has become less effective and expensive over time.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

User shared 2.5-year progress using finasteride for hair loss, showing significant improvement and reduced hair shedding. Persistence with finasteride led to thicker hair and fewer hair fall issues.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.